等待开盘 10-31 09:30:00 美东时间
-0.710
-7.97%
科技股惨遭血洗!纳指期货重挫近3%,英特尔暴跌近25%;特朗普发声:伊朗战事将“很快结束”;黄金白银齐跳水!现货黄金失守4000美元关口>>
10-30 20:26
业绩股齐升,Glaukos劲升33%,FTAI升逾17%;卡骆驰升逾25%,股价创近两年新高;Carvana升近16%,Q3销额、销量及净利润均实现双位数高增长>>
10-30 16:08
Bausch Health shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY26 sales guidance above estimates. Also, the company announced a $50 million buyback plan.
10-29 04:38
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase its common shares ("Common Shares") for a total aggregate purchase price of up to US$50 million (the "Share Repurchase Program...
10-29 04:23
Bausch Health Companies (NYSE:BHC) reported quarterly earnings of $1.77 per share which beat the analyst consensus estimate of $1.29 by 37.21 percent. This is a 52.59 percent increase over earnings of $1.16 per share from the same period last year. The company reported quarterly sales of $2.941 bill...
10-29 04:04
Bausch + Lomb raised its 2026 revenue and adjusted EBITDA guidance after Q3 sales rose 7% and adjusted EBITDA increased 34%, led by pharmaceuticals and surgical implantables.
10-29 00:01
(来源:医疗器械创新网) 2026年10月12日,全球眼健康领域的头部企业博士伦(Bausch + Lomb,NYSE/TSX:BLCO)对外公布,其&nbs...
10-13 17:00
Preliminary Update on 2026 Guidance2 Based on preliminary third-quarter results, Bausch + Lomb and Bausch Health currently expect to raise full-year 2026 adjusted EBITDA excluding Acquired IPR&D1 guidance.3 The companies are currently in a blackout period and will provide additional details when the...
10-12 18:48
Shares of Tempest Therapeutics Inc (NASDAQ:TPST) rose sharply in pre-market trading after the California-based clinical-stage biotechnology company announced an exclusive option agreement with Hebei Senlang Biotechnology Co., Ltd. According to the announcement, the agreement gives Tempest an exclusi...
09-16 17:04
Mr. Subramanian brings more than 20 years of finance, capital markets, business development and operational leadership experience across the biotechnology, pharmaceutical and healthcare sectors. Most recently, he served as Chief Financial Officer and Head of Business Development at Inozyme Pharma, w...
09-10 20:01